AM‐Pharma B.V., a biopharmaceutical company focused on the development ofrecAP (recombinant human Alkaline Phosphatase) for inflammatory diseases, hasrecruited the first 3 patients into its Phase II trial of recAP in sepsis-associated Acute Kidney Injury (AKI). The clinical trial is now underway in 9 countries, and will involve 50 sites.